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Does Screening for COPD by
Primary Care Physicians Have
the Potential to Cause More
Harm Than Good?
C ongratulations to the investigators of the Spi-rometry in Asthma and COPD: a Comparative
Evaluation (SPACE) program for carefully describ-
ing the excellent methods, but disappointing results,
of their Italy-wide study to determine whether office
spirometry performed by general practitioners (GPs)
improves the diagnosis of asthma and COPD.1 Since
2003, similar projects have been generously funded
in the United States. The SPACE program, which
enrolled 570 GPs, with spirometry training provided
by 57 pulmonary specialists, did not find a significant
advantage of office spirometry in improving the
diagnosis of asthma and COPD in the primary care
setting. However, a type II error cannot be excluded,
since the enrollment of participating patients
reached only about half of the goal determined by a
priori sample size calculations.
For several decades, I have personally been in-
volved in promoting the idea that primary care
providers (PCPs) [or GPs] should perform spirome-
try in their office.2 In 2000, the National Lung
Health Education Program recommended3 office
spirometry for COPD case-finding for adult smokers
being seen by their PCP. Since then, tens of millions
of dollars have been spent by industry for both
COPD case-finding in PCP settings and for screen-
ing programs designed to test very large samples of
the general populations of cities or entire countries
for airway obstruction.4 During the same period of
time, the definition of COPD has been considerably
broadened by the criteria of the Global Initiative for
Chronic Obstructive Lung Disease guidelines
(FEV1/FVC ratio,  70% [regardless of age and
FEV1 percent predicted]),5 so that two to three
times the number of people from a population
sample of adults now fit the new definition when
compared to traditional definitions.6–8
So, why should I now argue with success? What
possible harm could be done by the widespread
application of spirometry to detect COPD in its early
stages? Members of the National Lung Health Ed-
ucation Program recognized the weak evidence base
 5 years ago and called for well-designed studies to
determine whether PCPs could achieve acceptably
low misclassification rates for airway obstruction
when using simple office spirometers, and whether
knowledge of spirometry results substantially im-
proves smoking cessation rates.9 A new report10 from
the Agency for Healthcare Research and Quality
(AHRQ) emphasizes that this essential evidence
remains lacking and goes further to state that no
inhaled medications have been demonstrated to
improve COPD outcomes when prescribed to pa-
tients with an FEV1 of  50% predicted (Global
Initiative for Chronic Obstructive Lung Disease
stages 0, 1, and 2); and that many patients have been
prescribed inhaled medications for COPD, chronic
bronchitis, or emphysema, yet have entirely normal
spirometry findings. The financial implications of
these recommendations and guidelines are enor-
mous. Long-acting bronchodilators (and ultra-long-
acting bronchodilators) and inhaled corticosteroids
that have been prescribed for the treatment of
COPD have worldwide annual markets in the tens of
billions of dollars, and cost about $100 per month for
each elderly patient without insurance coverage.
Older adults in whom COPD has developed due
to smoking often have either a recognized or a
subclinical comorbidity (eg, cardiovascular disease,
glucose intolerance, osteoporosis, and ophthalmic
disease) that makes serious side effects, such as
malignant arrhythmias and osteoporotic fractures,
more likely when receiving long-term therapy with
these inhaled medications11–14 and, at best, tempo-
rarily reduces dyspnea on exertion in some patients
with severe airway obstruction. Smokers and PCPs
may also think that an inhaled medication is a
substitute for smoking cessation. Thus, psychologi-
cal, economic, and physical harm are all possible
when an “abnormal” spirometry result usually leads
to a prescription for an inhaled medication in an
adult smoker (with or without chronic cough,
phlegm, or wheeze). On a population-wide basis, the
possible benefits of the increased likelihood of smok-
ing cessation, temporary symptomatic relief, and
slightly reduced risk of a COPD exacerbation may
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not overcome the costs of testing and treating, and
the drug side-effects.10 However, the risk/benefit
ratio may be better for individually selected patients
and those who also have asthma.
The results of the SPACE study1 (see page 844)
suggest that problems with office spirometry will
remain even if medications for COPD are developed
that substantially improve the course of COPD in its
early stages, or if future studies demonstrate that
knowledge of abnormal spirometry results substan-
tially prompts physicians to offer more effective
smoking-cessation interventions, and prompts pa-
tients to successfully quit smoking. Even when of-
fered free training by local pulmonary specialists,
free spirometers, and free spirometry supplies, only
a fraction of GPs are interested in testing, and, of
those GPs who are interested, only a small fraction of
adult smokers (or asthmatic patients) in their prac-
tice are tested, even during the first few months of
enthusiasm. Most quit performing spirometry tests
altogether. Furthermore, the long-term accuracy of
the office spirometers was not evaluated; the misclas-
sification rates were not determined; and the cost,
benefits, adherence, and side effects of the resulting
interventions were not measured in this study.
I now agree with the authors of the superb AHRQ
report10 that, until more conclusive studies are per-
formed, spirometry should currently be offered only
to those smokers with dyspnea on exertion, and that
therapy with inhaled medications should be reserved
for those patients with a large bronchodilator re-
sponse (suggesting asthma), relief of dyspnea, or
severe airway obstruction (ie, FEV1  50% pre-
dicted) with a recent exacerbation that suggests a
high risk of hospitalization during the subsequent
year. The AHRQ report10 quotes large epidemio-
logic surveys showing that a surprising fraction of
patients with a diagnosis of COPD have normal
spirometry findings (ie, normal FEV1/FVC ratio and
a normal FEV1). Spirometry may add more value
when the lack of airway obstruction (after therapy
with albuterol) is used to rule out COPD, than it
does to confirm COPD in a smoker with respiratory
symptoms. Substantial financial savings and a reduc-
tion in serious drug side effects would result for both
the misclassified individual patients and entire coun-
tries if severe airway obstruction were routinely
confirmed before the prescription of chronically
inhaled medications for COPD.
Perhaps the focus should shift for a few years from
trying to convince PCPs to perform spirometry in
their office to providing high-quality (accredited)
respiratory care services in each community,15 to
which PCPs can refer their patients with dyspnea
due to asthma or COPD. These services could
include convenient smoking-cessation programs,
asthma education, spirometry, allergen skin testing,
exhaled nitric oxide measurements, pulmonary reha-
bilitation, long-term oxygen therapy, and chronic
disease management, all following evidence-based
clinical practice guidelines. The AHRQ report10
should also prompt the National Heart, Lung, and
Blood Institute to place a high priority on the
funding of a large multicenter study to determine
whether spirometry enhances the best practice of
smoking cessation in the primary care setting.
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Change in the BODE Index
Reflects Disease Modification
in COPD
Lessons From Lung Volume
Reduction Surgery
S ince the studies of Fletcher and colleagues,1 thenatural history of COPD has been associated with
the accelerated progressive decline of FEV1. FEV1
became the defining feature of the disease, and
because it predicted mortality, health costs, and
exacerbations,2–4 it constituted the logical target for
disease-modifying interventions. Unfortunately, the
diagnosis of COPD mandates that there be minimal
FEV1 response to bronchodilators, thus making
changes in FEV1 very difficult to achieve.
It is time to change the way in which we define
disease modification in COPD. Indeed, COPD is
associated with clinical manifestations not closely
related to the FEV1, such as worsened dyspnea,
reduction in exercise capacity, pulmonary hyperten-
sion, peripheral muscle weakness, and malnutrition.5
Furthermore, all of these factors appear to be more
important predictors of mortality than FEV1.6–9
Therefore, defining disease modification solely on
the improvement on the FEV1 does not reflect the
clinical manifestations of the disease and its ultimate
prognosis.
Borrowing from the experience of other medical
fields, disease modification in COPD can be defined
as any of the changes in a patient with COPD that
are caused by an intervention. The changes should
be maintained over time. If we accept certain pa-
tient-centered outcomes as important, changes in
any of them should be conceived as disease modify-
ing. One such intervention, lung volume reduction
surgery (LVRS), was popularized by Cooper et al10 as
a therapy for COPD patients with primarily upper-
lobe emphysema. Although the National Emphy-
sema Treatment Trial11 did not confer survival ad-
vantage to the surgical group as a whole, it resulted
in differences in health status and exercise capacity
in favor of LVRS and, at least in patients with
upper-lobe emphysema and poor exercise capacity, a
difference in survival after 3 years. It would be
extremely useful if there were “surrogate” markers
that could detect changes in a relatively short period
of time, and that were accurate in predicting patient
outcome. In this sense that marker could become a
tool in monitoring disease modification. The multi-
dimensional index BODE that includes the body
mass index (B), percentage of predicted FEV1 (O),
dyspnea (D), and the 6-min walk distance (E) is such
a tool,12 as it predicts mortality better than FEV1.
Furthermore, the variables that contribute to the
index are amenable to change by interventions and
thus make the BODE a potential tool to use in the
evaluation of disease-modifying interventions.
In this issue of CHEST (see page 873), Imfeld and
coworkers13 evaluated the power of short-term (3
months) changes in the BODE index in predicting
survival in 186 patients undergoing LVRS. Using C
statistics, the postoperative BODE index was a bet-
ter predictor of survival than FEV1, dyspnea score,
or 6-min walk distance. These results are in line with
those reported by Cote and Celli,14 who showed that
the BODE index can improve after pulmonary reha-
bilitation and that the magnitude of the change was
predictive of survival.
In the last few years, there have been important
changes in the way we view COPD. Unfortunately,
the regulatory agencies, the medical public at large,
and many in our midst still cling to the old concept
that it is only by changing FEV1 that we modify the
course of the disease. Imfeld and coworkers are to be
praised for helping show that there are disease-
modifying interventions and that tools such as the
BODE index can be used as markers defining ulte-
rior outcome.
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Boston, MA
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Tobacco Dependence
Treatment
Time To Change the Paradigm
F ifty years ago, I asked my radiologist father whymany of my grade school friends shunned an-
other who had asthma. “Well, David,” he responded,
“most people, and many physicians, believe that a
psychiatric disorder or a personality flaw causes
asthma, even though the scientific evidence does not
support that.”
Last summer, while presenting “Medical Manage-
ment of Tobacco Dependence” at the house-staff
noon conference at Stanford Medical, I related this
story. Their eyes popped. Jaws dropped. They were
astounded that 50 years ago anyone could have
thought asthma was a psychiatric disease. After they
recovered from their shock, I said I hoped that 20
years hence no one would believe the use of ciga-
rettes was a manifestation of a flaw in character or a
weak will. Rather, everybody—physicians and non-
physicians—would approach tobacco dependence
for the chronic medical disease it is, and recognizing
cigarette use as the primary symptom of tobacco
dependence.
In this article of CHEST (see page 979), Bars et al1
start the transformation in a phase II, open-label,
proof-of-concept study testing the hypothesis that
the number of cigarettes smoked per day determines
the severity of tobacco dependence and conse-
quently provides a way to provide more effective,
individualized pharmacotherapy, rather than the
standard “one-dose-fits-all” approach. Individualiz-
ing medication types, doses, and delivery systems, as
well medication duration of use, is common in
medical practice; clinical therapeutics for tobacco
dependence, however, is mired in outmoded phar-
macotherapeutic concepts. The clinical trial by Bars
et al1 on tobacco dependence is one of the first to
break out of that mold, using a treatment paradigm
similar to asthma: individualizing treatment based on
disease severity.
For having the scientific guts to break with en-
trenched (and nonscientifically validated) tradition
within the field of tobacco dependence, these au-
thors are to be commended. Their findings are of
critical importance to developing a more practical
and more clinically effective treatment model for im-
proving medical treatment of tobacco dependence.
Despite the documented safety and effectiveness
of any pair-wise combination of US Food and Drug
Administration-approved tobacco dependence med-
ications, boosting treatment effectiveness an addi-
tional 50 to 100% over either medication alone,2–9
physicians do not routinely use medication combina-
tions to improve outcome results. The most likely
reason for this omission is the lack an algorithm to
determine what medication combinations to use and
when, hence the importance of the present study.
The authors1 chose number of cigarettes smoked
per day as the independent variable to determine the
initial medication doses and delivery systems. Thus,
the “average” tobacco-dependent patient, compris-
ing 50% of this group from the New York Fire
Department (FDNY), smoked 20 to 30 cigarettes
per day and would have started treatment on two
different nicotine medications: an oral inhaler at
 12 cartridges per day, and a patch delivering 15
mg of nicotine over 16 h. Since each inhaler car-
tridge can deliver up to 4 mg of nicotine, the total
daily nicotine dose for the typical FDNY firefighter
could have been 63 mg of nicotine per day, a
threefold- to fourfold-higher dose than nicotine
patch labeling would recommend. Informatively,
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slightly  10% of the firefighters smoking 20 to 30
cigarettes per day actually used a more intense
regimen, since only 44%, not 50%, used the initial
regimen.
The nicotine patch functions like an asthma con-
troller medication and generally cannot relieve
acute, breakthrough, nicotine-withdrawal symptoms.
Nicotine patch takes a long time to reach maximum
serum concentration (Tmax) [both arterial and ve-
nous] of 6 to 8 h.10 The nicotine inhaler is 16 times
faster: Tmax  30 min.11,12 This oral inhaler delivers
nicotine to the brain faster and can thus relatively
acutely relieve breakthrough nicotine-withdrawal
symptoms. The nicotine oral inhaler does function
precisely like an asthma rescue inhaler.
In contrast, the light-smoking NYFD members,
smoking only one to five cigarettes per day, com-
prised 5% of the study population. They would have
started on only the nicotine inhaler, up to six car-
tridges per day, delivering only  24 mg of nicotine
per day: a 62% less total daily nicotine dose than the
typical tobacco-dependent patient in this cohort
would receive. This approach is similar to using an
albuterol inhaler as an as-needed rescue medication
to treat mild, intermittent asthma.
The heavy-smoking FDNY firefighter, smoking
 40 cigarettes per day and comprising only 5% of
the study population, would have started on one
controller medication (a higher patch dose [two
patches], delivering 30 mg of nicotine over 16 h) and
also two different nicotine-withdrawal symptom res-
cue medications: the oral inhaler ( 12 cartridges
per day) and the nicotine nasal spray for immediate/
crisis withdrawal symptom relief. Most importantly,
as the authors1 point out, four times more firefight-
ers than predicted—even though smoking  40
cigarettes per day—needed this unique, high-dose
nicotine medication paradigm in order to keep nic-
otine-withdrawal symptoms adequately suppressed.
This group would have used a total nicotine medi-
cation dose of 78 to 100 mg of nicotine per day, four
to seven times more than the ubiquitous, nonscien-
tifically determined nicotine patch labeling states: 15
mg over 16 h or 21 mg over 24 h. Because nicotine
medication doses were individualized, side effects
were nil.1
Finally, the protocol allowed for the addition of a
second controller medication, sustained-release bu-
propion, 150 mg, bid. As Table 1 in the article by
Bars et al1 stated, 14% of enrollees used sustained-
release bupropion, with most smoking  40 ciga-
rettes per day. Thus, it would appear that 14% of the
firefighters needed two controller medications, in-
cluding 30 mg of nicotine over 16 h transdermally,
and up to 88 mg of additional nicotine via rescue
medication delivery systems to keep nicotine-with-
drawal symptoms under adequate control.
Bupropion has a unique CNS mechanism of ac-
tion. It is both a dopamine and norepinephrine
reuptake inhibitor but without effect on serotonin.13
Nicotine, in contrast, activates multiple CNS path-
ways to release dopamine and norepinephrine, as
well as other neurotransmitters.14 These two tobacco
dependence-controller medications, sustained-re-
lease bupropion and nicotine patch, each acting via
different pharmacologic mechanisms of action in the
CNS, are similar to using two controller medications
in asthma.
Use of an algorithm of this type confirms two
important points: (1) individualizing and tailoring
medication combinations and doses, similar to the
current asthma standard-of-care, improves tobacco
dependence treatment effectiveness. Essentially ev-
ery published study heretofore found that treatment
effectiveness was inversely proportional to the num-
ber of cigarettes smoked per day. The worst smoking
cessation rates were seen in those who, pretreat-
ment, had smoked  20 cigarettes per day. More-
over, the number of cigarettes smoked per day,
pretreatment, inversely predicted the percentage not
smoking at any time after treatment start. Dale et
al15 found this relationship highly significant
(p  0.0001) across all doses of sustained-release
bupropion studied. Table 115 shows that 33% of
patients randomized to placebo who had smoked
 19 cigarettes per day had stopped smoking at the
end of study drug treatment, while only 4% who had
smoked  40 cigarettes per day could stop. Figure 4
in the study by Bars et al1 demonstrates that the
novel approach eliminates that inverse relationship.
At 3 months, approximately 50% of those who had
smoked 6 to 19 cigarettes per day had stopped, as
had approximately 50% who had smoked  40 cig-
arettes per day. Even more remarkable, at the
12-month evaluation point,1 9 months after all treat-
ment had stopped, treatment effectiveness was di-
rectly proportional to the pretreatment number of
cigarettes per day: approximately 30% of those who
had smoked 6 to 19 cigarettes per day had stopped,
but nearly twice that (approximately 50%) who had
smoked  40 cigarettes per day had stopped. This
finding is truly remarkable and without precedent. If
subsequent, randomized, double-blind studies con-
firm the unique, individualized approach of Bars et
al,1 we will be able to safely provide far more
effective tobacco dependence treatment for the pa-
tients in our office.
(2) Individualizing the dose of nicotine to as high
as  100 mg/d is safe, with no study participant
having a serious adverse drug event. The adverse
events reported were of mild intensity and little
www.chestjournal.org CHEST / 129 / 4 / APRIL, 2006 837
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consequence.1 If anything, these adverse events
seemed to relate more to resuming cigarette smok-
ing, rather than use of nicotine medications.1 The
adverse events of greatest potential cardiac concern,
chest pain and palpitations, fell significantly over
time, and particularly—surprise!—among those who
stopped smoking.1 It appears that even use of up to
100 mg of nicotine per day in the heaviest of smokers
did not produce toxicity.1
This study provides strong, compelling evidence
that individualizing pharmacotherapy can substan-
tially improve tobacco dependence treatment effec-
tiveness, with the heaviest cigarette users enjoying
50% treatment effectiveness—results unheard of
before the present study. The authors1 rightly point
out that their approach, based on number of ciga-
rettes smoked per day at study entry, although
intuitive and easy to employ, was not optimal.
Rather, the intensity of nicotine withdrawal, as easily
measured by the Fagerström Test for Nicotine De-
pendence,16 and the intensity of nicotine-withdrawal
symptoms, after stopping smoking, should provide a
superior algorithm to optimize treatment results.
This study shows us it is time to shed the artificial
and scientifically invalid dose and duration-of-use
constraints posed by nicotine medication labeling
and focus our attention—30 years after nicotine
polacrilex gum arrived on the global market—where
it should be: combining these valuable and safe
medications, including nicotine and bupropion, in
the most effective ways and using them as long as
necessary17–19 to improve smoking cessation rates
and optimize tobacco dependence treatment out-
come. After all, providing effective treatment so that
our patients have the proper tools to stop smoking is
the only way to prevent the progression of
COPD.20,21
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When Pulmonary Embolism
Treatment Isn’t Working
O bjectively proven acute pulmonary embolism(PE) is a satisfying disease to treat—unless the
treatment isn’t working. Supplementary oxygen for
the ventilation-perfusion component of hypoxia, ur-
gent anticoagulation IV or subcutaneously, and in-
tensive care for patients with more profound abnor-
malities are relatively easily accomplished. Intensive
care may include IV, peripherally administered
thrombolysis (absent a serious or absolute contrain-
dication) and IV crystalloid and pressor, with careful
attention to right ventricular filling, titrated to sup-
port cardiac output.
But some patients, including some without prior
known cardiopulmonary impairment, don’t improve.
Some worsen. When the evidence-based treatment
armory appears to be failing, deep concern ensues.
While we’re aware that about 12% of PE patients
will die from it,1 that outcome is difficult to accept
from a nonmalignant disease so frequently and care-
fully studied and usually handled so well. Of other
treatments to try at this stage, there is only one the
average intensivist can employ without calling an-
other specialist to urgently assume control of the
patient—repeat thrombolysis.
Repeat thrombolysis is not commonly employed
worldwide and there is no consensus about its use.
One recent metaanalysis of thrombolysis in PE did
not report any repeat thrombolysis,2 nor is it men-
tioned in either of two reports of large PE regis-
tries3,4. A randomized, partially blinded multi-center
trial of PE treatment from German centers5 found it
used 8% of the time in deteriorating patients but our
impression is that it is uncommonly used in North
America. North American physicians are more likely
to try other techniques, such as percutaneous embo-
lectomy, catheter fragmentation, angioplasty, and
thrombectomy,6 whose rationale is rapid relief of
central pulmonary artery obstruction by dispersion
of central clots to the periphery. Percutaneous cath-
eter embolectomy has also been reported to have a
higher success rate and lower mortality than surgical
embolectomy; surgery has a previously reported
average mortality of 30%,7 although sporadic and
more recent reports show improvement over that
figure.7,8
Concurrent controls are more valid than historical
ones. Desperate as we are to save the otherwise
salvageable patients dying from PE despite our
evidence-based treatment, who among us is using
acceptable methodology to study how to do that?
Meneveau and colleagues9 have done so and
carefully document a concurrently-controlled series
in this issue of CHEST (see page 1043). Although
their comparison of surgical thrombectomy on car-
diopulmonary bypass vs repeat systemic thromboly-
sis is neither randomized nor blinded, this one-of-a-
kind report of a substantial number of patients failing
first thrombolysis provides important clinical guid-
ance. Meneveau et al’s hospital dealt with failed
thrombolysis in one of two ways: repeat thrombolysis
or open surgical removal of clot with a forceps while
the heart was beating. The populations undergoing
one treatment or the other were similar, though not
identical—for example, there was a higher propor-
tion of patients with shock in the surgical group.
Results of other interventions such as mechanical
catheter fragmentation, percutaneous suction embo-
lectomy, secondary thrombolytic infusion directly
into a central clot, and of other possible techniques
are not reported in the paper. That should not be
viewed as a weakness of this report—too many
centers have no planned fallback management plans
whatsoever for such patients. There are other aspects
that make the study’s results inconclusive besides
heterogeneity of the patient populations: lack of a
statistically significant survival benefit, wide confi-
dence intervals around major bleeding rates and
outcome, and the multitude of uncertainties that
attend results of nonrandomized interventions. But
there is an observable trend toward a better in-
hospital outcome with rescue surgical thrombectomy.
The surgical management of such patients may not
be straightforward either. The objective is to estab-
lish hemodynamic stability with sufficient flexibility
to deal with the particular circumstances found in
the individual patient. Unless impossible, re-imaging
after failed thrombolysis should be done to establish
that surgically accessible clot remains proximal to the
first pulmonary artery branches. Median sternotomy
provides the best exposure and cardiopulmonary
bypass the best likelihood of stabilizing the circula-
tion. Ascending aortic and dual caval cannulations to
minimize blood in the operative field (or faster right
atrial cannulation if there is less time) give the
surgeon best control—this is precisely the technique
reported by Meneveau et al (others have reported
femoral-femoral bypass instituted percutaneously for
early stabilization10). Although cooling the heart and
cardiac arrest might provide better myocardial pro-
tection, they take extra time which may confer
significant additional risk, and these surgeons didn’t
employ them. Clot removal by ring forceps, and, on
occasion, cautious gentle balloon extraction of more
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distal clot (balloon extraction not reported by these
authors) can be employed. More distal clot can be
removed with circulatory arrest and under direct
vision but the bleeding risk is increased (Meneveau
et al did not do this). Skin-to-skin time, if things go
well, is about 1 h.
Some surgeons might consider embolectomy off-
pump11 but must be comfortable with that approach.
There is little if anything written about embolectomy
after systemic thrombolysis—bleeding has been
greatly feared, although there are case reports of safe
application of lytics after surgical embolectomy.12,13
As a practical matter, with the lytics off by the time
the patient reaches the surgical suite, their impact
could be minimal. These authors reported operating
within 72 h of lytic administration and had no fatal
bleeds in the 14 rescue embolectomy patients, indi-
cating that prior lytics is not an absolute contraindi-
cation.
This carefully documented report shows the mod-
ern feasibility of rescue surgical embolectomy after
failed thrombolysis for PE. It includes a comparison
to the alternative previously reported strategy of
repeat thrombolysis. Importantly, it provides a foun-
dation for physicians caring for PE patients at cen-
ters with cardiothoracic surgery to meet and formu-
late plans for how and when to call for help and what
kind of help to call for. These patients often present
in extremis after iatrogenic interventions intended to
help them (eg, bariatric, joint replacement, or cancer
surgery, or chemotherapy). Determining local crite-
ria and detailed plans for rescuing PE patients who
fail usual treatment is an important priority for our
specialties. Further cooperative clinical studies
should ensue. We congratulate Meneveau and col-
leagues for a carefully documented report of great
practical use.
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Second-Line Chemotherapy for
Non-small Cell Lung Cancer
T he article by Chen et al1 (see page 1031) is highlyinstructive from a number of perspectives. First
and foremost, the authors (and the reviewers) failed
to emphasize that this is a randomized phase II trial
and not a randomized phase III trial. Phase III trials
are true comparison trials and are sized so that clear
inferences can be made about the superiority (or lack
thereof) of any of the study arms tested. Randomized
phase II trials are designed to choose the best option
from among several with similar expected outcomes
and to test the feasibility of randomizing across
different modalities. They are, in reality, parallel
phase II trials. The required numbers for these trials
are far smaller than phase III trials. Their major use
is in eliminating the problems inherent in interpret-
ing the outcome of multiple phase II trials done at
separate institutions. It is not statistically valid to
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draw conclusions based on comparisons between the
study arms.2,3 Consequently, the inter-arm compar-
isons in this trial are invalid, although an actual phase
III trial confirmed these findings.4 Despite that,
there are several useful lessons from this trial.
The major lesson for pulmonologists from this
article is that second-line (and even third- and
fourth-line) therapy for metastatic non-small cell
lung cancer is common and reasonable for patients
who remain in “good” condition and who desire
further treatment.5–7 This is an important change in
clinical perspective. A decade ago, there were essen-
tially no active regimens for patients who failed
first-line chemotherapy. Indeed, up to the mid
1990s, the response rate for first-line chemotherapy
was only on the order of 20 to 25%, and only 25% of
patients with metastatic disease survived  1 year.8
Following the introduction of the taxanes, gemcitab-
ine and navelbine, in the mid-1990s, the response
rates have climbed and 1-year survival is closer to
50%, with 20 to 30% of patients with metastatic
disease surviving  2 years.9,10 The later introduc-
tion of the epidermal growth factor receptor
(EGFR)-targeted agents, gefitinib and erlotinib,11
has added another level of response and disease
control that has served to prolong survival in the
second-line setting. Most recently the addition of
bevacizumab, an angiogenesis inhibitor, to paclitaxel
plus carboplatin resulted in a significant improve-
ment in survival, although there is a small subset of
patients with severe and even fatal hemorrhage.12
When I first joined the American College of Chest
Physicians in 1993, there were still debates about
whether patients should receive any chemotherapy
for metastatic lung cancer. We are, thankfully, well
beyond those discussions as demonstrated by the
appearance of this article in CHEST (see page 1031).
Docetaxel was, for a period, the only agent ap-
proved by the US Food and Drug Administration
(FDA) for this indication, and that is a lesson in
itself. The FDA approval process bears no relation-
ship to the actual utility of any regimen compared to
another. The company need only show that the
outcome is superior to no treatment or to some other
inferior therapy. Several other agents are now ap-
proved for use in this setting, including pemetrexed
(an antifol13) and erlotinib (an EGFR inhibitor11).
Pemetrexed has been shown to have equal efficacy
with lower toxicity in a phase III randomized trial.13
In practice, oncologists try to choose a regimen that
is non–cross-resistant with the regimen that just
failed and which the patient can tolerate. The data
on weekly therapy have been a bit confusing. There
are no reports that it is superior to traditional every
3-week therapy, only that in some settings that it may
be less toxic.
A second lesson from this trial is the importance of
pharmacogenomics. It is clear that Asian patients
have very different response rates and toxicities to
several common chemotherapy regimens including
docetaxel14 and other taxanes.15 In addition, the
response rate to the EGFR inhibitors, gefitinib or
erlotinib, is significantly higher in Asian patients,
especially young, female patients who have lung
cancer despite a negative smoking history.16 This has
now been correlated with a much higher rate of
EGFR mutations in this group of patients.16 This is
not an issue of racial profiling; it is a matter of what
works and doesn’t work in patients, and needs to be
factored in to studies and day-to-day clinical decision
making.
It is frustrating that this article was not the
randomized study that we need but rather another
tidbit of information that suggests benefit. Despite at
least one true randomized trial4 suggesting equal
efficacy and lower toxicity, the type II error is large
enough that significant differences may still exist that
favor more intensive doses every 3 weeks. It is not
yet time to leap to the conclusion that weekly
therapy is better. The only certainty we have to date
is that the reimbursement for weekly therapy is
superior.
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A Step in the Right Direction With a
Long Road Ahead
I n this issue of CHEST (see page 905), Mikita andParker1 demonstrate that ambulatory vocal cord
dysfunction (VCD) patients, who likely had an un-
derlying somatoform disorder, had significantly more
physician visits and subspecialty visits (particularly
pulmonary) during the year prior to their VCD
diagnosis than matched control subjects with mod-
erate persistent asthma, which is the disorder that
VCD often mimics.
The VCD diagnostic approach of Mikita and
Parker1 is impressive from two perspectives. Because
of their role in determining soldier fitness for duty,
they implemented an aggressive evaluation for unex-
plained dyspnea, typically including a comprehensive
assessment for bronchial hyperreactivity. Conse-
quently, they were able to exclude concomitant
asthma in 84% of their 25 VCD patients. Ironically,
the identified VCD patients were largely retirees and
dependents rather than active duty military.
Second, the authors state that they followed the
standardized laryngoscopic procedure and diagnostic
criteria for VCD.2 These criteria evolved from the
endoscopic findings that we described in 19833 in
the first report of VCD presenting as asthma. To
summarize, when laryngoscopy is performed utiliz-
ing adequate topical anesthesia in symptomatic pa-
tients, the presence of inspiratory or inspiratory and
expiratory vocal cord adduction with a posterior
glottic chink confirms the diagnosis of VCD. The
findings are illustrated in Figure 1.
It is of concern that the present study reveals that
VCD was not recognized despite multiple encounters
with pulmonary physicians over the year prior to diag-
nosis. So why is it that, after all these years, there is such
difficulty in understanding and diagnosing VCD?
The first answers are obvious: (1) it is a relatively
uncommon condition; (2) the disorder closely mim-
ics asthma; (3) intermittent symptoms make endo-
scopic confirmation logistically difficult; and (4) by
the very nature of a somatoform disorder, diagnosis
of the condition is elusive. Another problem is that
the definition of the term VCD has also become
elusive. We originally selected the term VCD to
identify a very specific clinical syndrome that had
defined endoscopic features and mimicked asthma.3
Over time, VCD has become a very loosely applied
descriptor for inspiratory or isolated expiratory vocal
Figure 1. Laryngoscopic findings obtained during inspiration in
a symptomatic patient shows adduction of the true vocal cords
anteriorly, and the glottis narrows to a small posterior diamond-
shaped chink. An additional feature is that the false vocal cords
adduct, obscuring the laryngeal ventricles.
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cord adduction, either with or without the presence
of the posterior chink. Furthermore, the term VCD
has been applied to an ever-expanding array of
clinical presentations. There are a number of addi-
tional diseases or disorders that are manifested by
abnormal vocal cord motion during breathing. They
likely have different medical or psychological etiolo-
gies and constitute a spectrum of clinical presenta-
tions with varying severity. Confusion will continue if
a spectrum of disorders is collectively lumped to-
gether as VCD.
Clarity is further obscured if what has been loosely
identified as VCD limited to the expiratory phase
may not be dysfunctional at all. Adduction of the
vocal cords at the end of exhalation is normal.2
Higenbottam4 demonstrated that adduction of the
vocal cords occurred in early exhalation when
healthy volunteers underwent histamine broncho-
provocation. Though expiratory vocal cord adduction
in patients with obstructive lung disease may be
pathophysiologic under certain conditions, we
should not jump to conclusions. Higenbottam5
showed that patients with airway obstruction had
early expiratory adduction of the vocal cords. The
most marked expiratory adduction occurred with the
lowest FEV1 values. Collett and coworkers6 showed
that vocal cord adduction occurs during mid-exhala-
tion in asthmatic patients with experimentally in-
duced bronchoconstriction. The key insight is that
the reversal of the glottic obstruction occurred with
continuous positive airway pressure. This finding
suggests that expiratory adduction in asthma patients
may contribute to hyperinflation, allowing a benefi-
cial reduction in persistent inspiratory muscle activ-
ity during exhalation.
Confusion persists regarding the potential coexist-
ence of asthma in patients with a somatoform disor-
der that meets the laryngoscopic criteria for VCD. In
these patients, glottic obstruction often occurs on
expiration as well as on inspiration. Therefore, expi-
ratory flow may be limited on spirometry and may
mimic asthma. Figure 1 in the original description of
this disorder3 shows obstruction of the expiratory
flow-volume relationship in addition to inspiratory
flow limitation in patient 5. The study was performed
while the patient was symptomatic, and the results
could be interpreted as VCD with concomitant
asthma. However, subsequent bronchoprovocation
studies excluded asthma. The pitfalls of diagnosing
concomitant asthma based on an expiratory obstruc-
tive pattern on spirometry and bronchoprovocation
studies have been recognized.2,7–9 Noninvasive, prac-
tical, reliable, appropriately sensitive, specific, and eas-
ily interpreted tools that allow partitioning of the
resistances in the upper and lower airways are needed
to further our understanding of the physiologic and
pathophysiologic roles of the larynx in lung disease.
The message is clear. We need to move away from
using the term VCD as a catch-all descriptor for
vocal cord adduction during breathing. A greater
understanding of physiologic vs pathophysiologic
alterations in the glottic aperture is required. Future
prospective studies must objectively, meticulously,
and precisely define other diseases and disorders
affecting the glottis during breathing. We need to
become “splitters” rather than “lumpers.” Physio-
logic and anatomic correlations are key.
Though the prevalence of VCD is low, Mikita and
Parker1 have confirmed a significant negative impact
on health-care utilization. The plethora of case re-
ports are testimony to impaired quality of life. It is
high time to conduct appropriate scientific inquiries,
including prospective, comprehensive multicenter
trials at institutions with the commitment and re-
sources that are necessary to maximize our under-
standing of conditions that have been collectively
lumped together under the term VCD.
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